Aberrant epigenetic regulation of FZD3 by TET2 is involved in ovarian cancer cell resistance to cisplatin

References

• Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151–156.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ding JX, Tao X, et al. Goserelin can inhibit ovarian cancer proliferation and simultaneously protect ovarian function from cisplatin: an in vitro and in vivo study. J Chemother. 2013;25(2):96–103.
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen L, Chen R, et al. miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway. J Chemother. 2022;34(1):35–44.
   PubMed Web of Science ®Google Scholar
• Yang L, Xie HJ, Li YY, et al. Molecular mechanisms of platinumbased chemotherapy resistance in ovarian cancer (review). Oncol Rep. 2022;47(4):82.
   PubMed Web of Science ®Google Scholar
• Seagle BL, Dandapani M, Yeh JY, et al. Wnt signaling and survival of women with High-Grade serous ovarian cancer: a brief report. Int J Gynecol Cancer. 2016;26(6):1078–1080.
   PubMed Web of Science ®Google Scholar
• Meng Z, Liu Q, Liu Y, et al. Frizzled-3 suppression overcomes multidrug chemoresistance by wnt/beta-catenin signaling pathway inhibition in hepatocellular carcinoma cells. J Chemother. 2023;1–9.
   PubMed Web of Science ®Google Scholar
• Wan F, Chen F, Fan Y, et al. Clinical significance of TET2 in female cancers. Front Bioeng Biotechnol. 2022;10:790605.
   PubMed Web of Science ®Google Scholar
• Li D, Guo B, Wu H, et al. TET family of dioxygenases: crucial roles and underlying mechanisms. Cytogenet Genome Res. 2015;146(3):171–180.
   PubMed Web of Science ®Google Scholar
• Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30(7):733–750.
   PubMed Web of Science ®Google Scholar
• Tucker DW, Getchell CR, McCarthy ET, et al. Epigenetic reprogramming strategies to reverse global loss of 5-Hydroxymethylcytosine, a prognostic factor for poor survival in high-grade serous ovarian cancer. Clin Cancer Res. 2018;24(6):1389–1401.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ai H, Fan X, et al. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1. Biol Res. 2020;53(1):18.
   PubMed Web of Science ®Google Scholar
• Freimund AE, Beach JA, Christie EL, et al. Mechanisms of drug resistance in High-Grade serous ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):983–996.
   PubMed Web of Science ®Google Scholar
• Kharat SS, Ding X, Swaminathan D, et al. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability. Sci. Signal. 2020;13(645):eaba8091.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330–339.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu Z, Zhang Y. Expression and prognostic impact of FZDs in pancreatic adenocarcinoma. BMC Gastroenterol. 2021;21(1):79.
   PubMed Web of Science ®Google Scholar
• Xiang M, Huang Y, Dai C, et al. MiR-340 regulates the growth and metabolism of renal cell carcinoma cells by targeting frizzled class receptor 3. Arch Pharm Res. 2021;44(2):219–229.
   PubMed Web of Science ®Google Scholar
• Zhu GQ, Wang Y, Wang B, et al. Targeting HNRNPM inhibits cancer stemness and enhances antitumor immunity in wnt-activated hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2022;13(5):1413–1447.
   PubMed Web of Science ®Google Scholar
• Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumour cell heterogeneity and drug resistance. Drug Resist Updat. 2012;15(1-2):21–38.
   PubMed Web of Science ®Google Scholar
• Martinez-Useros J, Martin-Galan M, Florez-Cespedes M, et al. Epigenetics of most aggressive solid tumours: pathways, targets and treatments. Cancers (Basel). 2021;13(13):3209.
   PubMed Web of Science ®Google Scholar
• Zhang LY, Li PL, Wang TZ, et al. Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer. Arch Gynecol Obstet. 2015;292(4):891–897.
   PubMed Web of Science ®Google Scholar
• Song C, Wang L, Wu X, et al. PML recruits TET2 to regulate DNA modification and cell proliferation in response to chemotherapeutic agent. Cancer Res. 2018;78(10):2475–2489.
   PubMed Web of Science ®Google Scholar
• Kim SI, Lee JW, Lee M, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2018;148(2):375–382.
   PubMed Web of Science ®Google Scholar
• Duan H, Yan Z, Chen W, et al. TET1 inhibits EMT of ovarian cancer cells through activating wnt/beta-catenin signaling inhibitors DKK1 and SFRP2. Gynecol Oncol. 2017;147(2):408–417.
   PubMed Web of Science ®Google Scholar
• Zhao H, Lu J, Yan T, et al. Opioid receptor signaling suppresses leukaemia through both catalytic and non-catalytic functions of TET2. Cell Rep. 2022;38(4):110253.
   PubMed Web of Science ®Google Scholar
• Puig I, Tenbaum SP, Chicote I, et al. TET2 controls chemoresistant slow-cycling cancer cell survival and tumour recurrence. J Clin Invest. 2018;128(9):3887–3905.
   PubMed Web of Science ®Google Scholar
• Zhou K, Guo H, Zhang J, et al. Potential role of TET2 in gastric cancer cisplatin resistance. Pathol Res Pract. 2019;215(11):152637.
   PubMed Web of Science ®Google Scholar
• Xu H, Wang X, Zhang Y, et al. GATA6-AS1 inhibits ovarian cancer cell proliferation and migratory and invasive abilities by sponging miR-19a-5p and upregulating TET2. Oncol Lett. 2021;22(4):718.
   PubMed Web of Science ®Google Scholar
• Peng D, He A, He S, et al. Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma. Int J Biol Sci. 2022;18(3):995–1007.
   PubMed Web of Science ®Google Scholar
• Eyres M, Lanfredini S, Xu H, et al. TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes. Gastroenterology. 2021;161(2):653–668.e16.
   PubMed Web of Science ®Google Scholar
• Kopp B, Khoury L, Audebert M. Validation of the gammaH2AX biomarker for genotoxicity assessment: a review. Arch Toxicol. 2019;93(8):2103–2114.
   PubMed Web of Science ®Google Scholar
• Kiss RC, Xia F, Acklin S. Targeting DNA damage response and repair to enhance therapeutic index in Cisplatin-Based cancer treatment. IJMS. 2021;22(15):8199.
   Google Scholar
• Katoh M. WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets. 2008;9(7):565–570.
   PubMed Web of Science ®Google Scholar
• Takebe N, Miele L, Harris PJ, et al. Targeting notch, hedgehog, and wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–464.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh M, Akbarzadeh S, Majidinia M. Targeting notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer. Pathol Res Pract. 2020;216(11):153158.
   PubMed Web of Science ®Google Scholar
• Xu YP, Lv L, Liu Y, et al. Tumour suppressor TET2 promotes cancer immunity and immunotherapy efficacy. J Clin Invest. 2019;129(10):4316–4331.
   PubMed Web of Science ®Google Scholar
• Leekha A, Gurjar BS, Tyagi A, et al. Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. J Cancer Res Clin Oncol. 2016;142(12):2503–2514.
   PubMed Web of Science ®Google Scholar